Head and neck cancer can recur after robotic surgery, including TORS. The risk depends heavily on the original stage, whether margins were clear, HPV status and whether lymph nodes were involved. HPV-positive oropharyngeal cancers have significantly lower recurrence rates than HPV-negative disease. Most recurrences appear within the first two years. After five years without disease, the risk drops sharply.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Head and neck cancer recurrence after TORS is real, but the numbers are more encouraging than most patients expect, especially for HPV-positive disease. The surveillance schedule isn’t optional, it’s what catches recurrence early enough to treat it. A recurrence found at three months on clinical examination is a very different situation from one found a year later when the patient stopped coming for follow up.”

Stage, margins, biology and nodal status. All four feed into the risk.

• Surgical margin status: Clear margins after TORS significantly reduce local recurrence risk. Close or positive margins raise it. Some patients need adjuvant radiation to the primary site specifically because of margin findings on pathology.
• Lymph node involvement: Positive nodes at surgery mean higher risk of regional and distant recurrence. Neck dissection, performed alongside or after TORS, addresses regional nodes. Positive nodes usually trigger adjuvant radiation or chemoradiation.
• HPV status: HPV-positive oropharyngeal cancer, base of tongue and tonsil, has consistently better outcomes than HPV-negative disease. Three-year recurrence rates for HPV-positive TORS patients in published series sit below 15 percent. HPV-negative disease is more aggressive and recurs more often.
• Stage at surgery: Stage I and II disease treated with TORS alone has low recurrence rates. Stage III and IV disease with nodal involvement needs adjuvant treatment and carries a higher long-term recurrence risk even when surgery is successful.

For patients whose recurrence workup or salvage plan involves further minimally invasive surgery, robotic cancer surgery remains an option for selected recurrences in anatomically accessible sites.

Structured surveillance. Not passive monitoring.

• Clinical examination schedule: Every 6 to 8 weeks in the first year, every 3 months in year two, then less frequently. The surgeon examines the primary site, neck and oral cavity at every visit. This is when most recurrences are found first.
• Nasendoscopy: Flexible scope examination of the primary site including base of tongue, tonsil, pharynx and larynx. Allows direct visualisation of areas not visible on external examination. Done at each follow up.
• PET-CT imaging: At 3 to 6 months post-treatment to confirm complete response. Repeated if symptoms develop or examination raises concern. The most sensitive tool for detecting occult regional or distant recurrence.
• Salvage options: Local recurrence after TORS can sometimes be re-resected robotically. Regional neck recurrence may be salvage dissected. Distant metastases are managed with systemic treatment. Early detection is what keeps salvage surgery on the table.

For patients wanting to understand what TORS involves and what the procedure itself achieves, our blog on TORS surgery covers the full picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs TORS for oropharyngeal and base of tongue cancers, MIND neck dissection, and RABIT thyroid surgery, integrating recurrence surveillance into the post-surgical plan from the first consultation so patients understand the follow up commitment before they leave theatre.

High-volume TORS surgery means the margin decisions, neck dissection planning and adjuvant therapy discussions happen with a surgeon who reads this anatomy every week, not occasionally. That familiarity is what separates a good outcome from a preventable recurrence. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Most cancer pain is chronic and managed with medication. But some pain in cancer patients signals something acute and structural. Obstruction, perforation, bleeding, spinal cord compression. These aren’t pain management problems. They’re surgical problems. And the window between symptom onset and irreversible damage can be hours, not days.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Cancer patients and families sometimes wait too long with sudden severe pain because they assume it’s part of the disease. Sometimes it is. But sometimes it’s a perforation or a cord compression that needs an operating theatre or emergency imaging within hours. The rule I give families is simple. If the pain is sudden, severe and different from what’s been there before, go to a surgeon the same day. Don’t manage it at home.”

Four situations change cancer pain from chronic to urgent.

• Bowel obstruction: Crampy, colicky, worsening abdominal pain with bloating, no bowel movements and vomiting. Colon, ovarian and peritoneal cancers are common causes. If the bowel perforates, it becomes a life-threatening emergency within hours. Go to hospital, not a GP.
• Perforation: Sudden onset, severe abdominal pain, rigid abdomen, fever. A tumour has eroded through the bowel wall or stomach. Air under the diaphragm on X-ray confirms it. Needs emergency surgery. Minutes matter here.
• Haemorrhage: Sudden severe pain in the abdomen or flank alongside dropping blood pressure, rapid pulse or visible blood in stool or urine. Tumour bleeding can be catastrophic. Stable patients may be embolised. Unstable ones need the operating theatre.
• Spinal cord compression: Sudden severe back pain with progressive leg weakness, numbness or loss of bladder or bowel control. Bone metastases compressing the spinal cord. Same-day MRI and often emergency surgery or radiation within 24 hours. Every hour of delay reduces the chance of neurological recovery.

For cancer patients who reach emergency surgery, robotic cancer surgery is available for appropriate elective cases but true surgical emergencies are managed with whatever approach gets the patient safe fastest.

The distinction is in the character of the pain, not just the intensity.

• Sudden onset vs gradual: Chronic cancer pain builds over days or weeks. Surgical emergency pain often strikes sharply within minutes. A patient who was comfortable two hours ago and is now writhing needs urgent assessment, not a dose increase.
• New location or new character: Pain in a familiar site that suddenly shifts character, from dull ache to sharp cramp or constant burning, suggests something structural has changed. Obstruction, bleeding and perforation all change the pain character before the clinical signs appear.
• Associated features: Fever with abdominal pain. Leg weakness with back pain. Absence of bowel sounds with distension. These combinations move the assessment from pain management into emergency surgery territory immediately.
• Failure to respond to opioids: Visceral pain from obstruction or perforation often doesn’t respond to typical opioid doses the way chronic cancer pain does. A patient taking regular morphine who reports no relief from additional doses has a warning sign that something acute is happening.

For patients and families wanting to understand how cancer surgery decisions are made generally, our blog on cancer surgery explains the full clinical picture including when urgency applies.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He manages surgical emergencies in cancer patients including bowel obstruction, perforation, haemorrhage and post-operative complications, working with the emergency and ICU teams at KIMS Hospital to stabilise and operate when the clinical picture demands it.

What makes surgical emergencies in cancer patients different from standard emergencies is the background disease. Getting it right requires a surgeon who understands both the oncological context and the acute presentation, not just one or the other. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

The appendix sits next to the colon, but cancer arising there is a different disease entirely. Different cell types, different spread pattern, different staging system, different treatment. Most appendix cancers are slow-growing mucin-producing tumours. Colon cancer is overwhelmingly adenocarcinoma. Treating one like the other is a clinical mistake with real consequences.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients come in having been told it’s just colon cancer in the appendix. It isn’t. The biology is different, the staging is different, and the treatment is completely different. Appendix cancer with peritoneal spread needs cytoreductive surgery and HIPEC, not standard colorectal chemotherapy. Getting that distinction right at the start is the difference between a potentially curative operation and the wrong treatment entirely.”

Four things set them apart. At every level.

• Different tumour types: Most appendix cancers are low-grade mucinous neoplasms, goblet cell carcinoids or well-differentiated neuroendocrine tumours. Colon cancer is almost always adenocarcinoma from the colonic lining. Different cell origin. Different biological behaviour. Different prognosis.
• Different spread pattern: Colon cancer travels through lymphatics and blood to reach the liver and lungs. Appendix cancer, when it ruptures, seeds mucin directly across the peritoneal surfaces. That’s pseudomyxoma peritonei. It coats the abdomen rather than travelling to distant organs via the bloodstream.
• Different staging approach: Colon cancer uses TNM staging based on depth of invasion and nodal spread. Appendix cancer with peritoneal involvement uses the Peritoneal Cancer Index to measure the extent of abdominal surface disease. Entirely different system, entirely different criteria for what’s resectable.
• Different systemic chemotherapy response: FOLFOX and FOLFIRI, standard colorectal regimens, have very limited activity in low-grade appendiceal mucinous tumours. The biology doesn’t respond the same way. Applying colon cancer chemotherapy to appendix cancer produces poor results because the target is wrong.

For patients whose appendix cancer requires surgical removal as part of their treatment plan, robotic cancer surgery provides minimally invasive right hemicolectomy with precision and faster recovery than open approaches.

The treatment is specific to how this cancer spreads. Not interchangeable with colon cancer.

• Right hemicolectomy for localised disease: Cancer confined to the appendix without peritoneal seeding. Remove the appendix and the right colon together. No HIPEC needed at this stage. Surveillance follows.
• CRS and HIPEC for peritoneal spread: When appendix cancer has seeded the peritoneal surfaces, cytoreductive surgery removes all visible disease across the abdomen. Heated intraperitoneal chemotherapy follows immediately in the same operation. Not palliative. For selected patients it’s potentially curative.
• Pseudomyxoma peritonei: A ruptured appendix tumour has released mucin throughout the abdomen. Managed with CRS and HIPEC at experienced centres. Five-year survival above 50 percent in published series. Not a death sentence if the right team is involved.
• Watch and wait for very early LAMN: Low-grade appendiceal mucinous neoplasm, no rupture, no peritoneal involvement, confined to the appendix wall. Appendicectomy alone may be sufficient. Close surveillance required afterwards.

For patients who want to understand what HIPEC involves and what survival outcomes look like for appendix cancer specifically, our blog on HIPEC surgery covers it in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs CRS and HIPEC for appendix cancer with peritoneal spread, right hemicolectomy for localised disease, and presents every appendix cancer case to the tumour board so the plan reflects the actual biology of the tumour, not a default colon cancer protocol.

The difference between being treated as a colon cancer patient and being treated as an appendix cancer patient with peritoneal disease is the difference between the wrong chemotherapy and a potentially curative operation. That distinction is what MACS Clinic exists to make. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

In a narrow but clearly defined group of patients, yes. Very early, low-grade uterine cancer in young women who want to preserve fertility can be managed with hormonal therapy rather than surgery. The criteria are strict. Outside them, hysterectomy remains the standard treatment.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Uterine preservation in endometrial cancer is not a compromise. For the right patient, grade 1 stage IA disease with no myometrial invasion, hormonal therapy has published response rates above 70 percent and pregnancy outcomes that are genuinely encouraging. But patient selection is everything. This is not a route for any uterine cancer patient who wants to avoid surgery. The tumour board has to confirm the case fits the criteria before we consider it.”

Strict criteria apply. All four need to be met.

• Grade 1 endometrioid adenocarcinoma only: The most common and least aggressive subtype. High-grade histology, serous, clear cell or carcinosarcoma, are not candidates. Those need surgery without exception.
• Stage IA, no myometrial invasion: Cancer confined to the endometrium, not grown into the uterine muscle wall. MRI confirms this. Any myometrial invasion, even superficial, puts the patient outside preservation criteria.
• Strong desire to preserve fertility: Uterine preservation is a fertility-sparing decision, not a convenience one. Patients who have completed their family are offered hysterectomy, which remains the most reliable cure with the lowest recurrence risk.
• Willingness for intensive surveillance: Hormonal therapy requires hysteroscopy and biopsy every 3 to 6 months to confirm response. No response within 6 months means surgery. Patients must commit to this schedule fully.

For patients who proceed to minimally invasive robotic hysterectomy after hormonal therapy fails or at any stage of uterine cancer, robotic cancer surgery delivers precise pelvic surgery with faster recovery than open approaches.

Most uterine cancer patients fall here. The indications are clear.

• Stage IB and above: Cancer has grown into the myometrium or beyond. Hormonal therapy cannot reach or control disease that has invaded the muscle wall or spread further. Surgery is the only curative option.
• High-grade histology: Grade 2, grade 3, serous, clear cell or carcinosarcoma subtypes. Aggressive biology. Hormonal therapy has no meaningful role. Robotic radical hysterectomy with lymph node dissection is the standard approach.
• Failed hormonal therapy: No complete response confirmed on biopsy by 6 months. Continuing hormonal therapy beyond this risks allowing disease to progress. Hysterectomy is offered without further delay.
• Completed family or no fertility wish: For women who don’t need fertility preservation, hysterectomy removes the cancer and eliminates the risk of recurrence in the remaining uterus. The safest path when fertility isn’t the goal.

For patients who want to understand what uterine cancer curability means across stages and treatment types, our blog on uterine cancer curable explains the full picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic radical hysterectomy with lymph node dissection for uterine cancer, evaluates every eligible young patient for hormonal preservation at the tumour board, and ensures fertility goals are part of the treatment conversation from the very first consultation.

That fertility-first discussion at diagnosis, not as an afterthought once the surgical plan is already set, is what gives young women with uterine cancer a real choice rather than a decision made for them. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Bladder preservation is possible in bladder cancer, and for the majority of patients it’s the standard path. Around 75 percent of diagnoses are non-muscle invasive. The tumour hasn’t reached the bladder muscle. Those cases are almost always managed without removing the bladder. Even muscle invasive disease has a preservation route, chemoradiation combined with initial surgery, that delivers comparable outcomes to cystectomy in the right patients.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Bladder removal is not the automatic answer for every muscle invasive bladder cancer. Trimodal therapy, TURBT followed by concurrent chemoradiation, has published outcomes comparable to cystectomy in the right patient. The decision rests on tumour characteristics, bladder function, patient fitness, and whether the cancer responds to the initial resection. The tumour board makes that call with all four factors on the table.”

Three situations support bladder preservation. Each has clear criteria.

• Non-muscle invasive bladder cancer: Stages Ta, T1 and carcinoma in situ. The tumour hasn’t grown into the bladder muscle. TURBT removes it endoscopically. No open surgery, no cystectomy. Intravesical BCG or chemotherapy follows to reduce the chance of it coming back.
• Trimodal therapy for muscle invasive: TURBT removes as much visible tumour as possible. Concurrent chemoradiation follows. Works best in single tumours, no hydronephrosis, complete or near-complete initial resection and a bladder that still functions well.
• Partial cystectomy in rare cases: A small number of patients with a single accessible tumour and adequate remaining bladder capacity can have just that segment removed. Strict patient selection. Not the majority.
• Response-guided approach: Some centres restage with cystoscopy and biopsy after initial treatment. Complete responders are followed closely. Salvage cystectomy is available if disease persists or returns.

For patients whose bladder cancer requires robotic surgery whether TURBT, partial or radical cystectomy, robotic cancer surgery brings precision and faster recovery compared to open approaches.

Some situations make bladder removal the safest clinical choice.

• Muscle invasive, not trimodal-eligible: Multifocal tumours, hydronephrosis, incomplete initial TURBT, or poor bladder function. These features make chemoradiation unlikely to achieve durable control. Radical cystectomy is the standard.
• No response to chemoradiation: If restaging after trimodal therapy shows residual or recurrent muscle invasive disease, salvage cystectomy becomes necessary. Continuing bladder preservation after a failed response adds risk without benefit.
• High-grade recurrent non-muscle invasive: Multiple BCG failures with high-grade recurrent disease or progression toward muscle invasion. The bladder is no longer responding to bladder-sparing treatment. Cystectomy earlier is better than cystectomy later.
• Extensive or locally advanced disease: T4 tumours involving adjacent organs, or disease where the bladder itself is structurally compromised. Preservation is no longer functionally or oncologically sound.

For patients at the earliest stage where preservation is most achievable, our blog on bladder cancer warning signs explains what early symptoms look like and why they matter so much.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic TURBT, robotic partial cystectomy and robotic radical cystectomy for bladder cancer, evaluates every muscle invasive case for trimodal therapy eligibility at the tumour board, and ensures bladder preservation is considered before cystectomy is recommended.

That preservation-first conversation at the first consultation, rather than defaulting to cystectomy as the path of least resistance, is what gives bladder cancer patients a complete picture of their options before any decision is made. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.